Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from TNXP

Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years

On Friday, the U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals Holding Corp.’s (NASDAQ:TNXP) Tonmya (cyclobenzaprine HCl sublingual tablets) for fibromyalgia in adults.

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have rallied 30% over the past five sessions, though are marginally lower Thursday afternoon, as investors anticipate a key catalyst for the company.

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are building on recent gains, trading higher as investor focus intensifies on a key, upcoming catalyst. Here’s what investors need to know.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are trading sharply higher Tuesday morning following the release of the company’s second-quarter financial results and operational update.

Pharma Frenzy: Volatility Ignites Biotech Sector

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

EXCLUSIVE: Tonix Pharmaceuticals CEO Highlights Advantages Of Company's Monkeypox Vaccine In Development

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are soaring Monday after the World Health Organization (WHO) declared monkeypox a public health emergency of global concern.

Why Tonix Pharmaceuticals Stock Is Soaring

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading higher Wednesday after the company announced that the United States Patent and Trademark Office issued a patent to Tonix titled, "Synthetic Chimeric Poxviruses."

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Tonix Pharmaceuticals Q1 Earnings

Recap: Tonix Pharmaceuticals Q1 Earnings

Tonix Pharmaceuticals (NASDAQ:TNXP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has

Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets)

Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 (intranasal potentiated oxytocin) in a Phase 2 trial as a potential treatment for binge eating disorder. The Phase 2 clinical trial is expected to start in 2H of 2022. TNX-1900 is also in development for the treatment…

Tonix Pharma Inks Research Pact For Oxytocin In Eating Disorder

Tonix Pharma Inks Research Pact For Oxytocin In Eating Disorder

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has

Organisations

the US Food and Drug Administration

Massachusetts General Hospital

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

340,538 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play